News Monte Rosa Therapeutics, Inc.

Stocks

GLUE

US61225M1027

Biotechnology & Medical Research

Market Closed - Nasdaq 02:30:00 14/11/2026 am IST			5-day change	1st Jan Change
9.370 ^USD	+0.64%		-11.35%	-40.24%

10/11	Monte Rosa Therapeutics Presents Preclinical Data On MRT-8102 In Gout	CI
05/11	Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026	CI

All News

Mentions Relevance

7d5.wnPzeOwYsDXpub4rozEPV8P2B8Ot_rVlqf0CLqQSPOw.sEW3NaFAx3Kw1M5HzwlMLq-zQLrmlOoJ6KcxV8hFDKK3MpU9rnb-YYfIhg

10/11	Monte Rosa Therapeutics Presents Preclinical Data On MRT-8102 In Gout	CI
09/11	Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2026 on the Potential of MRT-8102 in Gout	GL
05/11	Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026	CI
05/11	Earnings Flash (GLUE) Monte Rosa Therapeutics, Inc. Reports Q3 Collaboration Revenue $54.4M, vs. FactSet Est of $33.9M	MT
05/11	Monte Rosa Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates	GL
04/11	Monte Rosa Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	GL
02/11	Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences	GL
28/10	Monte Rosa Therapeutics Announces Second Phase 2 Clinical Study Initiation for VAV1-Directed Molecular Glue Degrader MRT-6160	CI
28/10	Monte Rosa Therapeutics Announces Milestone Achievement Associated with Second Phase 2 Clinical Study Initiation for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)	GL
12/10	UBS Adjusts Price Target on Monte Rosa Therapeutics to $19 From $17, Maintains Buy Rating	MT
03/10	Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	GL
01/10	Monte Rosa Therapeutics Announces Positive Data From GFORCE-1 Phase 1 Study Evaluating MRT-8102	CI
01/10	Monte Rosa Therapeutics, Inc. - Special Call
01/10	Monte Rosa Therapeutics Says MRT-8102 Showed Biomarker Improvements in Phase 1 Study	MT
01/10	Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk	GL
01/10	HC Wainwright Initiates Monte Rosa Therapeutics at Buy With $25 Price Target	MT
01/10	Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk	GL
08/09	Monte Rosa Therapeutics Initiates Phase 2 Clinical Study for Vav1-Directed Molecular Glue Degrader MRT-6160	CI
08/09	Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)	GL
03/09	Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	GL
01/09	Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences	GL
24/08	Monte Rosa Therapeutics Doses First Patient in Phase 2 Prostate Cancer Study	MT
24/08	Monte Rosa Therapeutics Doses First Patient In MODeFIRe-1 Phase 2 Study Of MRT-2359 In Combination With Apalutamide In Patients With AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer	CI
24/08	Monte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer	GL
06/08	Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI